ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
9.87
+0.12 (1.23%)
Oct 8, 2026, 3:25 PM EDT - Market open
ImmunityBio Revenue
ImmunityBio had revenue of $51.24M in the quarter ending June 30, 2026, with 93.91% growth. This brings the company's revenue in the last twelve months to $165.79M, up 192.92% year-over-year. In the year 2025, ImmunityBio had annual revenue of $113.29M with 668.31% growth. That makes ImmunityBio the 18,828th largest company in the world by revenue and 3,005th in the United States.
Revenue (ttm)
$165.79M
Revenue Growth
+192.92%
P/S Ratio
61.82
Revenue / Employee
$239,931
Employees
691
Market Cap
10.46B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 113.29M | 98.54M | 668.31% |
| Dec 31, 2024 | 14.75M | 14.12M | 2,270.58% |
| Dec 31, 2023 | 622.00K | 382.00K | 159.17% |
| Dec 31, 2022 | 240.00K | -694.00K | -74.30% |
| Dec 31, 2021 | 934.00K | 329.00K | 54.38% |
| Dec 31, 2020 | 605.00K | -1.60M | -72.52% |
| Dec 31, 2019 | 2.20M | 2.16M | 4,585.11% |
| Dec 31, 2018 | 47.00K | 2.00K | 4.44% |
| Dec 31, 2017 | 45.00K | 1.00K | 2.27% |
| Dec 31, 2016 | 44.00K | -192.00K | -81.36% |
| Dec 31, 2015 | 236.00K | -405.00K | -63.18% |
| Dec 31, 2014 | 641.00K | 41.00K | 6.83% |
| Dec 31, 2013 | 600.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.41B |
| Halozyme Therapeutics | 1.66B |
| Madrigal Pharmaceuticals | 1.28B |
| Bio-Techne | 1.22B |
| Axsome Therapeutics | 776.57M |
| Arrowhead Pharmaceuticals | 669.50M |
| Krystal Biotech | 440.48M |
| Twist Bioscience | 431.80M |
IBRX News
- 6 hours ago - ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium - Business Wire
- 6 days ago - ImmunityBio rises 12.4% - TheFly
- 6 days ago - ImmunityBio rises 11.6% - TheFly
- 8 days ago - ImmunityBio rises 12.3% - TheFly
- 4 weeks ago - ImmunityBio put volume heavy and directionally bearish - TheFly
- 1 month ago - ImmunityBio appoints Kim as Vice Chairman - TheFly
- 1 month ago - ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman - Business Wire
- 2 months ago - ImmunityBio reports Q2 EPS (22c) vs. (10c) last year - TheFly